The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental There’s a new way for doctors to treat the ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...